Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial - Laterre, PF; Pickkers, P; Marx, G (Intensive Care Med, 2021)
et al.